# Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

> **NCT00365417** · PHASE2 · COMPLETED · sponsor: **NSABP Foundation Inc** · enrollment: 45 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Capecitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00365417
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-02
- **Final completion:** 2009-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365417, "Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00365417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*